CN Patent

CN114502539A — 包含雄激素受体的抑制剂的药物组合物和组合及其用途

Assigned to University of British Columbia · Expires 2022-05-13 · 4y expired

What this patent protects

本公开总体上涉及包含雄激素受体调节剂或抑制剂和诸如抗雄激素物质的第二治疗活性剂的药物组合物和组合。特别地，本公开涉及可用于治疗各种癌症例如乳腺癌和前列腺癌的药物组合物和组合。

USPTO Abstract

本公开总体上涉及包含雄激素受体调节剂或抑制剂和诸如抗雄激素物质的第二治疗活性剂的药物组合物和组合。特别地，本公开涉及可用于治疗各种癌症例如乳腺癌和前列腺癌的药物组合物和组合。

Drugs covered by this patent

Patent Metadata

Patent number
CN114502539A
Jurisdiction
CN
Classification
—
Expires
2022-05-13
Drug substance claim
No
Drug product claim
No
Assignee
University of British Columbia
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.